Dedifferentiated liposarcoma presenting with unexplained leukocytosis

  1. Carla M. Martín-Abreu 4
  2. Ana Godoy-Reyes 4
  3. Fernando Armas-González 4
  4. Onán Pérez Hernández 4
  5. Carmen Nieves Hernández-León 1
  6. Beatriz Esquivel-Vázquez 2
  7. Cristina Vila-Zarate 3
  8. Emilio González-Reimers 4
  1. 1 Servicio de Anatomía Patológica. Hospital Universitario de Canarias. Universidad de La Laguna
  2. 2 Departamento de citogenética. Hospital Universitario de Canarias. Universidad de La Laguna
  3. 3 Servicio de Cirugía General y Digestiva. Hospital Universitario de Canarias. Universidad de La Laguna
  4. 4 Servicio de Medicina Interna. Hospital Universitario de Canarias. Universidad de La Laguna
Show affiliations +
Journal:
Majorensis: Revista Electrónica de Ciencia y Tecnología

ISSN: 1697-5529

Year of publication: 2019

Issue: 15

Pages: 24-28

Type: Article

DIALNET GOOGLE SCHOLAR lock_openOpen access editor

More publications in: Majorensis: Revista Electrónica de Ciencia y Tecnología

Abstract

Introduction: Liposarcoma usually presents as an asymptomatic incidental tumor or with symptoms associated with the mass effect. Manifestations related to the inflammatory response against the neoplastic disease are uncommon, especially in early stages, and paraneoplastic features, including leukocytosis, are exceptional. Case report: We present the case of a patient who developed progressive leukocytosis that first appeared three months before admission. A mass was discovered both by computerized tomography and magnetic resonance, and after a non-conclusive first biopsy, in which intense neutrophilic infiltration suggested a pyomyositis, a dedifferentiated liposarcoma was identified when the tumor was excised. Leukocytosis, that reached 41.52x109/L two days before surgery, abated to 12.13x109/L. Discussion: In a review of 2007 only 6 cases of liposarcoma with leukocytosis had been described, and only a few cases have been reported afterwards. We hypotheses about the relation between this leukocytosis and the liposarcoma

Bibliographic References

  • Crago AM, Dickson MA. Liposarcoma: multimodality management and future targeted therapies. Surg Oncol Clin N Am 2016; 25(4): 761-73
  • Dickson MA, Schwartz GK, Keohan ML, et al. Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial. JAMA Oncol 2016; 2(7): 937-40.
  • Engström, K., Willén, H., KåbjörnGustafsson, C., Andersson, C., Olsson, M., Göransson, M., Järnum, S., Olofsson, A., Warnhammar, E, Aman, P. The myxoid/round cell liposarcoma fusion oncogene FUS-DDIT3 and the normal DDIT3 induce a liposarcoma phenotype in transfected human fibrosarcoma cells. Am J Pathol 2006; 168(5),1642-53
  • Guetz G, Mariani P, Freneaux P, Pouillart. Paraneoplastic syndromes in cancer: case 2 Leucocytosis associated with liposarcoma recurrence: original presentation of liposarcoma recurrence: Multirrence. J Clin Oncol 2004; 22(11): 2242-3.
  • Hara A Retroperitoneal Dedifferentiated Liposarcoma Producing Granulocyte Colony-Stimulating Factor Accompanied by Spontaneous Rupture: PET/CT Imaging of a G-CSF Producing Tumor. Case Rep Oncol 2011; 4: 236–241 6. Kumarasamy NA, Gayer G Retroperitoneal sarcomas. Semin Ultrasound CT MR 2011; 32(5): 422-32
  • Lee HS, Yu JI, Lim DH, Kim SJRetroperitoneal liposarcoma: the role of adjuvant radiation therapy and the prognostic factors. Radiat Oncol J 2016; 34(3): 216-222.
  • Macneill AJ, Miceli R, Strauss DC, Bonvalot S, Hohenberger P, Van Coevorden F, Rutkowski P, Callegaro D, Hayes AJ, Honoré C, Fairweather M, Cannell A, Jakob J, Haas RL, Szacht M, Fiore M, Casali PG, Pollock RE, Raut CP, Gronchi A, Swallow CJ. Post-relapse outcomes after primary extended resection of retroperitoneal sarcoma: A report from the Trans-Atlantic RPS Working Group. Cancer2017; 12(11): 1971-1978
  • Matthyssens, Creytens, Ceelen. Retroperitoneal liposarcoma: current insights in diagnosis and treatment. Front Surg 2015, 2(4): 1-16
  • Nakamura AL, Tanaka S, Takayama H, Sakamoto M, Ishii H, Kusano M, Onizuka Y, Ota S, Mitamura K. A mesenteric liposarcoma with production of granulocyte colony-stimulating factor. Intern Med1998, 37(10): 884-90.
  • Nassif, Tseng, Borges, Chen, Eisenberg. Recent advances in the management of liposarcoma. F1000Res 2016; 22(5): 2907
  • Nathenson MJ, Barysauskas CM, Nathenson RA, Regine WF, Hanna N, Sausville E Surgical resection for recurrent retroperitoneal leiomyosarcoma and liposarcoma. World J Surg Oncol 2018; 16(1): 203.
  • Pitrak DL. Effects of granulocyte colonystimulating factor and granulocytemacrophage colony stimulating factor on bactericidal functions of neutrophils. Curr Opin Hematol 1997; 4(3): 183-190.
  • Ray-Coquard, Blay, Italiano, Le Cesne, Penel, Zhi, Heil, Rueger, Graves, Ding, Geho, Middleton, Vassilev, Nichols, Nguyen Bui. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplifi ed, welldifferentiated or dedifferentiated liposarcoma: an exploratory proof-ofmechanism study. Lancet Oncol2012; 13: 1133–40
  • Sakamoto A, Matono H, Yoshida T, et al. Dedifferentiated liposarcoma with leukocytosis. A case report of G-CSFproducing soft-tissue tumors, possible association with undifferentiated liposarcoma lineage. World J Surg Oncol2007; 5: 131.
  • Schettini F, De Santo I, Rea CG, De Placido P, Formisano L, Giuliano M, Arpino G, De Laurentiis M, Puglisi F, De Placido S, Del Mastro L. CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors. Front Onco2018; 12: 608.
  • Shih, Lin, Li, Chen, Liu, Yang Dedifferentiated liposarcoma can induce a leukemoid reaction. Formosan Journal of Surgery2013; 47: 42-48
  • Van Arendonk KJ, He JA. Massive Retroperitoneal Mass With Leukocytosis. JAMA Surg2016.151(12): 1177-1178
  • Vijay A, Ram LRetroperitoneal liposarcoma: a comprehensive review.Am J Clin Oncol 2015, 38(2): 213-9
  • Wang LB, Mc Aneny D, Doherty G, Sachs T. Effect of intraoperative radiotherapy in the treatment of retroperitoneal sarcoma. Int J Clin Oncol 2017, 22(3): 563-568.
  • William W. Tseng, Neeta Somaiah, Alexander J. Lazar, Dina C. Lev, Raphael E. Pollock. Novel Systemic Therapies in Advanced Liposarcoma: A Review of Recent Clinical Trial Results. Cancers2013, 5(2): 529–549
  • Yong KL. Granulocyte colonystimulating factor (G-CSF) increases neutrophlic migration across vascular endothelium independent of an effect on adhesion: comparison with granulocyte macrophage colony stimulating factor. Br J Haematol 1996; 94(1):40-7
Data source: Dialnet